» Articles » PMID: 26067100

Assay Strategies for Identification of Therapeutic Leads That Target Protein Trafficking

Overview
Specialty Pharmacology
Date 2015 Jun 13
PMID 26067100
Citations 8
Authors
Affiliations
Soon will be listed here.
Abstract

Receptors, enzymes, and ion channels are traditional targets of therapeutic development. A common strategy is to target these proteins with agents that either activate or suppress their activity with ligands or substrates that occupy orthosteric sites or have allosteric interactions. An alternative approach involves regulation of protein trafficking. In principle, this approach enables 'rescue' of misfolded and misrouted mutant proteins to restore function, 'shipwrecking' of undesirable proteins by targeting them for destruction, and regulation of levels of partially expressed wild type (WT) proteins at their functional sites of action. Here, we present drug discovery strategies that identify 'pharmacoperones', which are small molecules that serve as molecular templates and cause otherwise misfolded mutant proteins to fold and route correctly.

Citing Articles

Acute Intermittent Porphyria: An Overview of Therapy Developments and Future Perspectives Focusing on Stabilisation of HMBS and Proteostasis Regulators.

Bustad H, Kallio J, Vorland M, Fiorentino V, Sandberg S, Schmitt C Int J Mol Sci. 2021; 22(2).

PMID: 33445488 PMC: 7827610. DOI: 10.3390/ijms22020675.


Rescue of mutant gonadotropin-releasing hormone receptor function independent of cognate receptor activity.

Smith E, Janovick J, Bannister T, Shumate J, Ganapathy V, Scampavia L Sci Rep. 2020; 10(1):10579.

PMID: 32601341 PMC: 7324376. DOI: 10.1038/s41598-020-67473-w.


A Pharmacological Chaperone Therapy for Acute Intermittent Porphyria.

Bustad H, Toska K, Schmitt C, Vorland M, Skjaerven L, Kallio J Mol Ther. 2019; 28(2):677-689.

PMID: 31810863 PMC: 7001003. DOI: 10.1016/j.ymthe.2019.11.010.


Screening of Chemical Libraries Using a Yeast Model of Retinal Disease.

Scott B, Wybenga-Groot L, McGlade C, Heon E, Peisajovich S, Chang B SLAS Discov. 2019; 24(10):969-977.

PMID: 31556794 PMC: 11670874. DOI: 10.1177/2472555219875934.


Folding and Misfolding of Human Membrane Proteins in Health and Disease: From Single Molecules to Cellular Proteostasis.

Marinko J, Huang H, Penn W, Capra J, Schlebach J, Sanders C Chem Rev. 2019; 119(9):5537-5606.

PMID: 30608666 PMC: 6506414. DOI: 10.1021/acs.chemrev.8b00532.


References
1.
Baell J, Holloway G . New substructure filters for removal of pan assay interference compounds (PAINS) from screening libraries and for their exclusion in bioassays. J Med Chem. 2010; 53(7):2719-40. DOI: 10.1021/jm901137j. View

2.
Janovick J, Maya-Nunez G, Conn P . Rescue of hypogonadotropic hypogonadism-causing and manufactured GnRH receptor mutants by a specific protein-folding template: misrouted proteins as a novel disease etiology and therapeutic target. J Clin Endocrinol Metab. 2002; 87(7):3255-62. DOI: 10.1210/jcem.87.7.8582. View

3.
Mecozzi V, Berman D, Simoes S, Vetanovetz C, Awal M, Patel V . Pharmacological chaperones stabilize retromer to limit APP processing. Nat Chem Biol. 2014; 10(6):443-9. PMC: 4076047. DOI: 10.1038/nchembio.1508. View

4.
Heiser V, Scherzinger E, Boeddrich A, Nordhoff E, Lurz R, Schugardt N . Inhibition of huntingtin fibrillogenesis by specific antibodies and small molecules: implications for Huntington's disease therapy. Proc Natl Acad Sci U S A. 2000; 97(12):6739-44. PMC: 18723. DOI: 10.1073/pnas.110138997. View

5.
Sun Y, Breydo L, Makarava N, Yang Q, Bocharova O, Baskakov I . Site-specific conformational studies of prion protein (PrP) amyloid fibrils revealed two cooperative folding domains within amyloid structure. J Biol Chem. 2007; 282(12):9090-7. DOI: 10.1074/jbc.M608623200. View